NVAC Vaccine Financing Stakeholder Forum

1
NVAC Vaccine Financing Stakeholder Forum

• A Distributors Perspective
• Presented by Brian Cox

2
Henry Schein, Inc. Overview

• Henry Schein is one of the largest distributors
  of vaccines in the USA
• Distribute over 80 vaccine skus through sales
  force of 2,000 team Schein members
• Vaccines are complemented by over 90,000
  additional skus

3
Henry Schein, Inc. Overview

• VFC distributor in 26 States and municipalities
• Currently averaging over 400 VFC orders per day
• Distributed 20 million influenza doses in 2003
• Provide exclusive distribution for a variety of
  vaccine manufacturers

4
Henry Schein, Inc. Overview

• Cover all trade classes including office-based
  physicians, GPOs, DoD contracts, vaccine
  clinics, public health, retail pharmacies, etc
• Henry Schein provides the valuable service of
  uniting health care practitioners with the
  products they need to deliver quality care

5
Recommendation 1

• Believe recommendation will improve immunization
  rates across all demographics
• Have concerns about crossover between insured and
  uninsured. How will this work?
• What leeway will insurance companies have in
  pricing the vaccine benefit? Impact to patients?

6
Recommendation 1

• What will happen with vaccines, like Td, that
  have a new calculated value less than the current
  market price?
• What will happen with new vaccines that are
  priced above the new calculated price? Will we
  end up with vaccines that are unavailable to
  certain demographics?

7
Recommendation 1

• If a voucher program is to be established, what
  would the incremental costs be if this were the
  only option? Are these costs offset by the
  benefits of the insurance mandate? Is it
  beneficial to have both a voucher and insurance
  mandate?

8
Recommendation 2

• Expanding the non-voting membership of ACIP is
  important under the new proposed system
• If not ACIP then another advisory body should be
  set up to work in conjunction with the ACIPs
  scientific contributions

9
Recommendation 3

• This should be considered integral to any
  wholesale change in the current vaccine financing
  system